Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VRPX |
---|---|---|
09:32 ET | 201 | 3.72 |
11:31 ET | 300 | 3.91 |
11:33 ET | 988 | 3.945 |
12:05 ET | 100 | 3.95 |
12:57 ET | 1500 | 3.9796 |
01:12 ET | 100 | 3.99 |
01:32 ET | 600 | 3.96 |
01:33 ET | 1500 | 4.02 |
02:24 ET | 900 | 4.04 |
02:26 ET | 1000 | 4.0303 |
02:29 ET | 1500 | 4.1136 |
02:45 ET | 1831 | 4.115 |
02:47 ET | 1256 | 4.2 |
02:49 ET | 955 | 4.2 |
03:02 ET | 100 | 4.26 |
03:16 ET | 1000 | 4.1979 |
03:34 ET | 430 | 4.2612 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Virpax Pharmaceuticals Inc | 4.4M | -0.4x | --- |
Biophytis SA | 4.1M | 0.0x | --- |
HST Global Inc | 4.5M | -30.8x | --- |
Alterola Biotech Inc | 4.4M | -1.2x | --- |
Burzynski Research Institute Inc | 4.7M | -3.9x | --- |
Artelo Biosciences Inc | 4.7M | -0.5x | --- |
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-11.62 |
Book Value | $14.15 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.